BGM Group Ltd. BGM
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
BGM Group Ltd. (BGM) is a healthcare company listed in the US with a market value of about $105M. In fiscal year 2025 it had revenue of $38M and net income of -$20M, a net margin of -52.6%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -5% a year, a 5-year average ROIC of -0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.
About BGM Group
BGM Group is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $50M in 2018 to $38M in 2025, a decline of about 4.0% a year. It was profitable in 5 of the last 8 years in our data. It spends 2% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | $25M | $46M | $65M | $57M | $50M | $46M | $50M |
| Net income | -$20M | -$1M | -$8M | $1M | $3M | $5M | $6M | $5M |
| Free cash flow | -$4M | $304105 | $132450 | $11M | -$1M | $5M | -$1M | $3M |
| EPS (diluted) | $-1.49 | $-0.11 | $-0.58 | $0.08 | $0.24 | $0.38 | $0.44 | $0.39 |
| Net margin | -52.6% | -5.8% | -16.7% | 1.7% | 5.5% | 10.1% | 12.8% | 10.3% |
| ROIC | -2.5% | -0.9% | -4.8% | 3.5% | 4.0% | 15.6% | 26.2% | 28.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is BGM Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does BGM Group pay a dividend?
Not currently.
Is BGM Group a good stock to buy?
We do not give buy or sell advice. BGM Group scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.